BD Names Dr. Carrie Byington To Board Of Directors

FRANKLIN LAKES, N.J., Oct. 22, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Carrie L. Byington has been appointed to the company’s board of directors, bringing the total number of directors to 13. Byington, 58, is executive vice president and head of University of California Health (UCH), where she... Read more

FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)

Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a month By continuously delivering medicine into the eye through a refillable implant, Susvimo may help people with nAMD maintain their vision with as few as... Read more

GE Healthcare Advances Precision Radiation Therapy Solutions with New Products, Partners and Solutions at #ASTRO21

Chicago – October 22, 2021: At this year’s ASTRO 2021 event, GE Healthcare will showcase over 15 innovative multi-modality radiation therapy solutions, offering medical practitioners imaging tools and support they need to improve patient-centered care and advance the practice of precision medicine. “GE Healthcare aims to drive improved patient outcomes through cutting-edge multi-modality radiation therapy... Read more

Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)

Lung cancer remains the leading cause of cancer-related deaths worldwide, with more than 2.2 million people diagnosed globally last year.1 The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may benefit from treatment with Tecentriq immunotherapy based on the results of the Phase III IMpower010 study. This new test expands Roche’s... Read more

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

SANTA CLARA, Calif., October 21, 2021  Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Gastric (stomach) cancer is the fifth most common cancer and... Read more

Xylem Expands Partnership with Imagine H2O to Support Water Innovation Entrepreneurs

Global Partnership Scales Imagine H2O’s Work with Entrepreneurial Water Solutions RYE BROOK, N.Y.–(BUSINESS WIRE)–Oct. 21, 2021– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s greatest water challenges has announced an expanded commitment to Imagine H2O, the leading water innovation accelerator and ecosystem for water entrepreneurs. As a global... Read more

Danaher Reports Third Quarter 2021 Results

WASHINGTON, Oct. 21, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the third quarter 2021.  All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended October 1, 2021, net earnings were $1.2 billion, or $1.54 per diluted common share which represents a 33.0% year-over-year increase... Read more

Olympus Announces New Cloud Solution to Streamline Life Science Research

A central hub for research data enables greater productivity at universities and labs October 20, 2021 Olympus is proud to start offering the Olympus Life Science Solution Cloud (OLSC) in Japan to streamline life science research at universities and laboratories. The OLSC provides researchers with a central hub to store and access data—including images, notes... Read more

Waters and University of Delaware Announce Bioprocessing Innovation Partnership, Plan 2022 Opening of Immerse Delaware Lab

Partnership will focus on developing analytical solutions to better characterize bioprocesses towards improved quality, yields and efficiency News Summary: Waters and University of Delaware announce a multi-year collaboration to develop technology for analytical characterization of manufacturing processes for biologics and novel modalities. Waters’ staff and university researchers will co-locate at Immerse™ Delaware, an Innovation and... Read more